SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer
Summary
This Nature paper identifies SLAMF6 as an inhibitory, drug-targetable receptor that dampens CD8+ T cell responses in cancer. Using mouse genetic models, antibody blockade and human T cell assays, the authors show that loss or antibody-mediated blockade of SLAMF6 boosts T cell activation, reduces exhaustion-like dysfunction, enhances anti-tumour responses in multiple tumour models, and reinvigorates chronically stimulated human T cells. Mechanistically, SLAMF6 signals via SHP-1 to limit TCR signalling. The team developed blocking human monoclonal antibodies (#21 and #23) that recapitulate the genetic phenotype without inducing a cytokine storm, and they report code and scRNA-seq analyses supporting expression of SLAMF6 in exhausted tumour-infiltrating CD8+ T cells. A patent has been filed on therapeutic use of the blocking mAbs.
Key Points
- SLAMF6 acts as a negative regulator of T cell activation and effector function; SLAMF6-deficient T cells show stronger proliferation, cytokine production and cytotoxicity.
- Blocking SLAMF6 with specific human monoclonal antibodies (#21 and #23) enhances T cell activation and improves tumour control in murine models (E.G7 and B16-OVA).
- SLAMF6 mediates inhibition through recruitment/activation of SHP-1, dampening TCR-proximal signalling events.
- Antibody blockade reverses exhaustion-like features in repeatedly stimulated murine and human T cells, increasing IFN-γ and TNF-α production and reducing exhaustion markers.
- scRNA-seq analysis shows SLAMF6 is expressed in tumour-infiltrating exhausted CD8+ T cell subsets (Tpex/Tex), supporting clinical relevance.
- Blocking mAbs did not trigger a systemic cytokine storm in treated mice, suggesting an acceptable safety signal in these preclinical tests.
- All custom analysis code is publicly available on GitHub and archived on Zenodo; no novel bulk RNA-seq data were generated.
- Authors have filed a patent on human SLAMF6 blocking antibodies, indicating translational intent and potential commercial development.
Content summary
The study combines mouse genetics (Slamf6 knockout), functional T cell assays, adoptive transfer tumour models, human primary T cell experiments and single-cell transcriptomics. SLAMF6-deficient T cells are more responsive to antigenic stimulation and better at tumour control. The authors generated and characterised human SLAMF6 monoclonal antibodies; two blocking mAbs reproduce enhanced T cell responses and reduced exhaustion in vitro and improved tumour control in vivo. Mechanistic experiments link SLAMF6 inhibition to lowered SHP-1-dependent suppression of TCR signalling. Single-cell RNA-seq from tumour-infiltrating CD8+ T cells shows SLAMF6 expression enriched in exhausted/progenitor-exhausted compartments, supporting the target’s relevance in human tumours. Safety assessments in mice found no evidence of cytokine-release syndrome under the tested conditions.
Context and relevance
This work sits squarely in the immune-checkpoint and adoptive-cell-therapy landscape. PD-1/CTLA-4 blockade transformed cancer care, but many patients remain refractory; identifying additional inhibitory receptors that can be targeted to reinvigorate exhausted T cells is a top priority. SLAMF6 is presented here as a novel checkpoint-like molecule with a clear mechanism (SHP-1 recruitment) and tractable therapeutic tools (blocking mAbs). For researchers and developers working on next-generation checkpoint inhibitors, combination immunotherapies or T cell engineering, SLAMF6 is now a compelling candidate for further preclinical and clinical evaluation. The public availability of code and the scRNA-seq contextualisation strengthen the translational case.
Why should I read this?
Quick version: if you care about making tired tumour T cells fight better, this paper punches above its weight. It shows SLAMF6 is a brake you can actually hit with antibodies to boost T cell activity without immediate runaway inflammation in mice — and they back it with human T cell data and single-cell maps. Read it to spot a plausible new checkpoint target and to save yourself hours trawling supplementary figures.
Author style
Punchy: This is a high-impact, translationally minded immunology paper. If you work in cancer immunotherapy or T cell biology, the findings are immediately actionable and worth close reading — from mechanism to antibody tools and single-cell evidence in human tumours.